U.S. jury says Bayer must pay $80 million to man in Roundup cancer trial

SAN FRANCISCO/NEW YORK (Reuters) – A U.S. jury on Wednesday awarded $80 million to a man who claimed his use of Bayer AG’s glyphosate-based weed killer Roundup caused his cancer, in the latest legal setback for the company facing thousands of similar lawsuits.

Edwin Hardeman (R), with his attorneys Jennifer Moore (L) and Aimee Wagstaff, speaks to the media, after having been awarded more than $80 million by a U.S. jury after Bayer AG’s weed killer Roundup was found liable for his non-Hodgkin’s lymphoma, at the Federal court in San Francisco, California, U.S., March 27, 2019. REUTERS/Alexandria Sage

The jury in San Francisco federal court said the company was liable for plaintiff Edwin Hardeman’s non-Hodgkin’s lymphoma.

It awarded $5 million in compensatory damages and $75 million in punitive damages to Hardeman after finding that Roundup was defectively designed, that Monsanto failed to warn of the herbicide’s cancer risk and that the company acted negligently.

Bayer bought Roundup maker Monsanto last year for $63 billion.

The company in a statement on Wednesday said it was disappointed with the jury’s decision and that it would appeal the verdict.

“This verdict does not change the weight of over four decades of extensive science and the conclusions of regulators worldwide that support the safety of our glyphosate-based herbicides and that they are not carcinogenic,” Bayer said.

The trial is only the second of more than 11,200 Roundup lawsuits set to go to trial in the United States. Previous litigation setbacks and a prior jury verdict against the company have sent Bayer shares plunging.

The verdict comes after the same jury on March 19 found Roundup to have been a “substantial factor” in causing Hardeman’s cancer, allowing the trial to proceed to a second phase to determine liability and damages. Bayer shares fell more than 12 percent after last week’s jury finding.

In the trial’s second phase, Hardeman’s lawyers were able to present previously excluded internal documents allegedly showing the company’s efforts to influence scientists and regulators about the widely-used product’s safety.

Lawyers for Hardeman were seen by a Reuters reporter cheering in the elevator outside the courtroom after the verdict was announced.

“As demonstrated throughout trial, since Roundup’s inception over 40 years ago, Monsanto refuses to act responsibly,” Hardeman’s lawyers said in a statement, adding that the company instead focused on “manipulating public opinion and undermining anyone who raises genuine and legitimate concerns about Roundup.”

‘HASN’T SUNK IN’

After the verdict, Hardeman told reporters he was “overwhelmed.”

“It hasn’t sunk in yet,” he said.

Hardeman’s case was considered a bellwether trial to help determine the range of damages and define settlement options for the more than 760 other federal cases pending in the same court before U.S. District Judge Vince Chhabria.

In the first trial phase of Hardeman’s case, the jury deliberated for more than four days before finding Roundup responsible for the man’s cancer. Bayer on Wednesday said that was an indication that jurors were “very likely divided over the scientific evidence.”

The company said its appeal would focus on legal rulings by Chhabria, who allowed some of Hardeman’s scientific experts to testify despite calling plaintiffs’ expert opinions “shaky” in a 2018 ruling.

But legal experts have noted that the 9th U.S. Circuit Court of Appeals, which oversees the San Francisco federal court, has generally been permissive in allowing expert testimony.

Monsanto’s Roundup was the first to contain glyphosate, the world’s most widely used weed killer. But it is no longer patent-protected and many other versions are available. Bayer does not provide sales figures for the product.

The U.S. Environmental Protection Agency, the European Chemicals Agency and other regulators have found that glyphosate is not likely carcinogenic to humans. The World Health Organization’s cancer arm in 2015 reached a different conclusion, classifying glyphosate as “probably carcinogenic to humans.”

In the first U.S. Roundup trial, another California man was awarded $289 million in August after a state court jury found Roundup caused his cancer. That award was later reduced to $78 million and is on appeal.

Hardeman’s case featured a significant difference from that trial after Chhabria decided to split cases before him into two phases: one to decide causation on purely scientific grounds, the other to determine Bayer’s potential liability and damages only if the jury first ruled that the weed killer was a substantial factor in causing cancer.

FILE PHOTO: Monsanto’s Roundup weedkiller atomizers are displayed for sale at a garden shop near Brussels, Belgium November 27, 2017. REUTERS/Yves Herman/File Photo

That decision had been seen as beneficial to Bayer. Legal experts said the jury’s verdict in the first phase of the Hardeman case was a significant setback, narrowing the company’s legal options going forward.

Chhabria has scheduled another bellwether trial for May and a third trial is likely to also take place this year. All three will be split into causation and liability phases.

Bayer is also scheduled to face another Roundup trial in California state court beginning on March 28 and at least two trials in Missouri state court in the fall.

Reporting by Alexandria Sage in San Francisco; Writing by Tina Bellon in New York; Editing by Bill Berkrot

Source

more recommended stories

  • Second opioid distributor charged over U.S. overdose crisis

    (Reuters) – An Ohio drug wholesale.

  • U.S. overdose deaths post annual drop for first time in two decades

    (Reuters) – U.S. overdose deaths dropped.

  • FDA finds ‘significant violations’ at India’s Strides plant

    (Reuters) – The U.S. Food and.

  • U.N. wants more urgency in AIDS fight as gains and funding fade

    LONDON (Reuters) – The global fight.

  • Oklahoma seeks to hold J&J responsible for opioid crisis as trial ends

    NORMAN, Okla. (Reuters) – Lawyers for.

  • Healthy living may help offset genetic risk of dementia: study

    LONDON (Reuters) – Living healthily with.

  • Democrats take aim as Trump abandons drug pricing plan

    WASHINGTON (Reuters) – Democrats see U.S..

  • U.S. appeals court blocks Trump administration birth control exemptions

    (Reuters) – A federal appeals court.

  • China vows to tackle dead pig scam amid swine fever epidemic

    FILE PHOTO: Piglets are seen by.

  • Alberta joins Ontario in pulling some CannTrust weed products

    TORONTO (Reuters) – Alberta is placing.

  • Trump administration pushes U.S. at-home kidney care, transplant availability

    NEW YORK/WASHINGTON (Reuters) – The Trump.

  • U.S. appeals court signals sympathy to bid to strike down Obamacare

    NEW ORLEANS (Reuters) – A federal.

  • U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

    (Reuters) – A federal judge on.

  • Intra-Cellular drug fails one of two bipolar depression studies; shares fall

    (Reuters) – Intra-Cellular Therapies Inc said.

  • China reports new African swine fever outbreak in Guangxi region

    BEIJING (Reuters) – China’s southwestern region.

  • Weed ban means no Rocky Mountain high for Canada’s Calgary Stampede

    CALGARY, Alberta (Reuters) – Canada’s Calgary.

  • Weightlifting better at reducing heart fat than aerobic exercise

    Obese people who engaged in resistance.

  • Sydney’s city council reviews use of Bayer’s Roundup weed killer amid cancer fears

    SYDNEY (Reuters) – Sydney’s city council.

  • Bulgaria confirms two cases of African swine fever

    SOFIA (Reuters) – Bulgaria has confirmed.

  • FDA approves Karyopharm Therapeutics’ blood cancer drug

    (Reuters) – The U.S. Food and.

  • Facebook to tackle content with misleading health claims

    FILE PHOTO: The Facebook logo is.

  • FDA ties three deaths to Edwards Lifesciences’ recalled heart devices

    (Reuters) – The U.S. Food and.

  • India asks its states not to partner with Philip Morris-funded foundation

    NEW DELHI (Reuters) – India’s health.

  • U.S. federal court delays adoption of healthcare rule on abortion

    FILE PHOTO – A imaging table.

  • China tightens vaccine management after scandals

    FILE PHOTO – A nurse prepares.

  • U.S wages lost to unpaid family care to hit $147 billion by 2050

    As the U.S. population ages, the.

  • U.S. ‘gag rule’ linked to 40% jump in abortions in parts of Africa

    LONDON (Reuters) – A decades-old U.S..

  • Study shows major real-world impact of cervical cancer vaccines

    LONDON, June 26 (Reuters) – Vaccination.

  • Glyphosate use will eventually end, Merkel says

    German Chancellor Angela Merkel attends a.

  • Unproven stem cell therapies often peddled by doctors without training

    At U.S. clinics advertising unproven stem.

  • Teleflex recalls breathing tubes worldwide after reports of 4 deaths

    (Reuters) – Teleflex Inc said on.

  • In border camps, Syrians rely on doctors in trucks and tents

    AZAZ, Syria (Reuters) – The Syrian.